Geode Capital Management
SNDX icon

Geode Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Geode Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.5M Buy
2,584,136
+427,078
+20% +$8.88M ﹤0.01% 1559
2026
Q1 		$50.4M Buy
2,157,058
+66,126
+3% +$1.44M ﹤0.01% 1487
2025
Q4 		$43.9M Sell
2,090,932
-399
-0% -$6.96K ﹤0.01% 1566
2025
Q3 		$32.2M Buy
2,091,331
+41,981
+2% +$549K ﹤0.01% 1748
2025
Q2 		$19.2M Buy
2,049,350
+26,365
+1% +$290K ﹤0.01% 1979
2025
Q1 		$24.9M Buy
2,022,985
+49,869
+3% +$703K ﹤0.01% 1784
2024
Q4 		$26.1M Sell
1,973,116
-3,966
-0.2% -$67.9K ﹤0.01% 1817
2024
Q3 		$38.1M Buy
1,977,082
+66,459
+3% +$1.37M ﹤0.01% 1608
2024
Q2 		$39.2M Buy
1,910,623
+132,075
+7% +$2.76M ﹤0.01% 1518
2024
Q1 		$42.3M Buy
1,778,548
+243,493
+16% +$5.43M ﹤0.01% 1468
2023
Q4 		$33.2M Buy
1,535,055
+174,135
+13% +$2.68M ﹤0.01% 1603
2023
Q3 		$19.8M Buy
1,360,920
+39,817
+3% +$753K ﹤0.01% 1830
2023
Q2 		$27.7M Buy
1,321,103
+93,502
+8% +$1.95M ﹤0.01% 1640
2023
Q1 		$25.9M Buy
1,227,601
+126,572
+11% +$3.15M ﹤0.01% 1630
2022
Q4 		$28M Buy
1,101,029
+132,900
+14% +$3.1M ﹤0.01% 1546
2022
Q3 		$23.3M Buy
968,129
+60,273
+7% +$1.35M ﹤0.01% 1625
2022
Q2 		$17.5M Buy
907,856
+52,441
+6% +$874K ﹤0.01% 1856
2022
Q1 		$14.9M Buy
855,415
+90,788
+12% +$1.53M ﹤0.01% 2083
2021
Q4 		$16.7M Buy
764,627
+31,407
+4% +$580K ﹤0.01% 2080
2021
Q3 		$14M Buy
733,220
+26,278
+4% +$438K ﹤0.01% 2210
2021
Q2 		$12.1M Buy
706,942
+140,019
+25% +$2.56M ﹤0.01% 2323
2021
Q1 		$12.7M Buy
566,923
+103,747
+22% +$2.34M ﹤0.01% 2199
2020
Q4 		$10.3M Buy
463,176
+51,163
+12% +$1.06M ﹤0.01% 2158
2020
Q3 		$6.08M Sell
412,013
-2,677
-0.6% -$40.8K ﹤0.01% 2278
2020
Q2 		$6.14M Buy
414,690
+81,432
+24% +$1.24M ﹤0.01% 2207
2020
Q1 		$3.65M Buy
333,258
+33,057
+11% +$310K ﹤0.01% 2327
2019
Q4 		$2.63M Buy
300,201
+13,963
+5% +$103K ﹤0.01% 2839
2019
Q3 		$2.14M Buy
286,238
+17,681
+7% +$161K ﹤0.01% 2908
2019
Q2 		$2.5M Buy
268,557
+70,951
+36% +$517K ﹤0.01% 2804
2019
Q1 		$1.04M Buy
197,606
+17,407
+10% +$99.3K ﹤0.01% 3148
2018
Q4 		$801K Buy
180,199
+6,768
+4% +$37.1K ﹤0.01% 3198
2018
Q3 		$1.4M Buy
173,431
+5,040
+3% +$35.9K ﹤0.01% 3078
2018
Q2 		$1.18M Buy
168,391
+13,835
+9% +$136K ﹤0.01% 3114
2018
Q1 		$2.2M Buy
154,556
+1,073
+0.7% +$11.4K ﹤0.01% 2706
2017
Q4 		$1.34M Buy
153,483
+22,803
+17% +$226K ﹤0.01% 2975
2017
Q3 		$1.53M Buy
130,680
+4,681
+4% +$57.4K ﹤0.01% 2894
2017
Q2 		$1.76M Buy
125,999
+27,037
+27% +$309K ﹤0.01% 2809
2017
Q1 		$1.36M Buy
98,962
+9,410
+11% +$97.7K ﹤0.01% 2866
2016
Q4 		$642K Buy
89,552
+2,517
+3% +$27.6K ﹤0.01% 3183
2016
Q3 		$1.32M Buy
87,035
+57,056
+190% +$750K ﹤0.01% 2797
2016
Q2 		$295K Buy
+29,979
New +$411K ﹤0.01% 3435

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management's SNDX Position: Q2 2026 in Review

Geode Capital Management increased its Syndax Pharmaceuticals (SNDX) stake by 20% in Q2 2026, buying an estimated $8.88M and bringing the position to 2,584,136 shares worth $56.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1559.

Geode Capital Management first reported a position in SNDX in Q2 2016 and has held it in 41 quarters since. 218 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Geode Capital Management held 2,584,136 shares of Syndax Pharmaceuticals worth $56.5M as of Q2 2026.
  • Geode Capital Management bought 427,078 Syndax Pharmaceuticals shares in Q2 2026, an estimated $8.88M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1559 holding.
  • Geode Capital Management first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 41 quarters since.
  • 218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.